Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study
about
HLA-DR15 haplotype and multiple sclerosis: a HuGE reviewNatural history of primary progressive multiple sclerosisHLA class II transgenic mice as models of human diseases.HLA-DQ polymorphism influences progression of demyelination and neurologic deficits in a viral model of multiple sclerosisHLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course.Absence of IFN-γ increases brain pathology in experimental autoimmune encephalomyelitis-susceptible DRB1*0301.DQ8 HLA transgenic mice through secretion of proinflammatory cytokine IL-17 and induction of pathogenic monocytes/microglia into the centraEnvironmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study.Genetic analysis of multiple sclerosis.Multiple sclerosis complexity in selected populations: the challenge of Sardinia, insular Italy.Definition of a 1.06-Mb region linked to neuroinflammation in humans, rats and miceHLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRbeta1 chain is associated with the clinical course of multiple sclerosisMultiple sclerosis genetics: leaving no stone unturned.HLA-DRB1 allele polymorphisms in genetic susceptibility to esophageal carcinoma.The relation between menarche and the age of first symptoms in a multiple sclerosis cohort.An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locusHLA-DQ6 (DQB1*0601)-restricted T cells protect against experimental autoimmune encephalomyelitis in HLA-DR3.DQ6 double-transgenic mice by generating anti-inflammatory IFN-gammaHLA-DQ8 (DQB1*0302)-restricted Th17 cells exacerbate experimental autoimmune encephalomyelitis in HLA-DR3-transgenic mice.Latitude and HLA-DRB1*04:05 independently influence disease severity in Japanese multiple sclerosis: a cross-sectional studyAntioxidant therapy in multiple sclerosis.Immunogenetics of drug-induced skin blistering disorders. Part II: synthesis.Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic miceA multi-hit hypothesis of bullous pemphigoid and associated neurological disease: Is HLA-DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading?Risk factors in multiple sclerosis: a population-based case-control study in Sicily. Background and methods.Interaction of loci within the HLA region influences multiple sclerosis course in the Sardinian population.Analysis of HLA DR2&DQ6 (DRB1*1501, DQA1*0102, DQB1*0602) haplotypes in Iranian patients with multiple sclerosis.Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis.Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin.HLA class II polymorphism in Saudi patients with multiple sclerosis.HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis.Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome.HLA-DRB1: genetic susceptibility and disability progression in a Spanish multiple sclerosis population.Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistanceA search for susceptibility genes in multiple sclerosisHeterogeneity at the HLA-DRB1 allelic variation locus does not influence multiple sclerosis disease severity, brain atrophy or cognition
P2860
Q28290714-E9770469-C97F-4A48-B3E6-BE81EE6B5477Q29391465-82432C72-FC57-4470-BF1D-48F0601FA274Q33713285-AF69BD5D-6F7A-43AC-9556-BBE86D8CBCB3Q33745499-8FFBD12D-12FA-4322-9157-5C8C912E7038Q33904555-9CBE6B3E-52DF-4DE4-91E1-D4425A32E306Q34518133-F1ED121C-CE27-455D-B576-E99C7419A88CQ34548374-10B2F52D-DE2C-42E9-8289-01B35768C864Q34590767-BBB7DDA6-6352-4D2F-B6F0-374A4BEC8B2CQ34722561-20479EE3-CCC8-4E8E-BCED-1AE0E219C0ECQ34898428-5B1307A9-60EB-4B0B-A3A5-1ECF4AB5E29DQ35465548-EE97AE5D-D756-430B-A3C2-9CA9B7118904Q35487679-699A0640-329A-422F-AC5A-0173673E525FQ36171871-093B9680-4E6D-4208-8DFD-1CA01408EC5EQ36209671-B5FC708F-A775-4351-ACCC-2B9109CE9577Q36501521-F37E517D-0237-4FAB-8C81-5F9C7589335FQ36693352-9944C21C-D168-429E-A616-77D0D0E066E1Q36958285-57B11A77-43A8-4403-9075-D15B7E2C1FCFQ37151283-A959D95A-7B8C-4E91-8615-DCF6C8AD02C3Q37237207-D2012E7B-43ED-4176-960F-7D52B80FA7A8Q37258404-47AF2620-F1D0-4BEF-97FF-005CFE6AFFA4Q37486715-EBC0D0BE-762C-41F3-9202-19AB96B1349EQ37883681-0C3F860F-FA72-4AE9-98FD-112FDF54F90FQ39094653-1743ED86-2D4F-494C-BFBF-6B1D5D64BEBAQ40637426-1C7F1B3F-8086-454C-AEE9-4C4205868C13Q44353815-ADDCB5E5-F5E9-4470-99D8-F87D8E9CABCFQ44957582-80F46BBA-53CD-4892-AB7C-5375D3F6D2F4Q46889094-BCFBAE39-7293-42D8-A380-BD5A5F5280D2Q47655500-CA9B849A-39AB-45ED-A86E-9B24B7914AE4Q47843189-1E6D2D7A-FDC4-43A8-AD87-2D6CC621E34EQ47947454-9D2BD0F3-F135-4DBF-B5C8-C55F60514A73Q47988514-DDFC602D-99E2-4839-AD0B-3A793D5AF26EQ48088336-DFF779DA-DBB0-4901-A104-C61A07A2B368Q54419877-D9CD8F8C-D358-44F2-B2CA-465B1509F30CQ57317727-DD651E58-7786-43F1-9FAC-8828283DE424Q57417488-80D88D44-C2F4-418A-BAF8-AA6DC7E2774EQ58863566-5A63EB15-443F-409D-86AA-6236045A6647
P2860
Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Major histocompatibility compl ...... f MS: a population-based study
@ast
Major histocompatibility compl ...... f MS: a population-based study
@en
Major histocompatibility compl ...... f MS: a population-based study
@nl
type
label
Major histocompatibility compl ...... f MS: a population-based study
@ast
Major histocompatibility compl ...... f MS: a population-based study
@en
Major histocompatibility compl ...... f MS: a population-based study
@nl
prefLabel
Major histocompatibility compl ...... f MS: a population-based study
@ast
Major histocompatibility compl ...... f MS: a population-based study
@en
Major histocompatibility compl ...... f MS: a population-based study
@nl
P2093
P3181
P356
P1433
P1476
Major histocompatibility compl ...... f MS: a population-based study
@en
P2093
A S Bissonet
B G Weinshenker
M Rodriguez
P Santrach
S K McDonnell
P3181
P356
10.1212/WNL.51.3.742
P407
P577
1998-09-01T00:00:00Z